

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : G01N 33/569, 33/68, C07K 15/00 C12P 21/00, A61K 39/395		A1	(11) International Publication Number: WO 92/08983 (43) International Publication Date: 29 May 1992 (29.05.92)
(21) International Application Number: PCT/CA91/00404 (22) International Filing Date: 18 November 1991 (18.11.91) (30) Priority data: 615,058 19 November 1990 (19.11.90) US (71) Applicant: QUEEN'S UNIVERSITY AT KINGSTON [CA/CA]; Kingston, Ontario K7L 3N6 (CA). (72) Inventors: SZEWCZUK, Myron, R. ; 378 Renda Street, Kingston, Ontario K7M 5Y1 (CA). MACFADDEN, Douglas, K. ; 228 Chatham Avenue, Toronto, Ontario M4M 2X6 (CA). KHAN, Rashid, H. ; 67 Village Drive, Apt. 907, Kingston, Ontario K7K 6K7 (CA).		(74) Agent: HICKS, Richard, J.; Patents & Licensing, Parteq Innovations, Queen's University, Kingston, Ontario K7L 3N6 (CA). (81) Designated States: AT, AT (European patent), AU, BB, BE (European patent), BF (OAPI patent), BG, BJ (OAPI patent), BR, CA, CF (OAPI patent), CG (OAPI patent), CH (European patent), CI (OAPI patent), CM (OAPI patent), DE (European patent), DK (European patent), ES (European patent), FI, FR (European patent), GA (OAPI patent), GB (European patent), GN (OAPI pa- tent), GR (European patent), HU, IT (European patent), JP, KP, KR, LK, LU (European patent), MC, MG, ML (OAPI patent), MR (OAPI patent), MW, NL (European patent), NO, PL, RO, SD, SE (European patent), SN (OAPI patent), SU*, TD (OAPI patent), TG (OAPI pa- tent). Published With international search report.	

(54) Title: HIV MARKER/AIDS VACCINE

(57) Abstract

HIV infected individuals have antibodies against HIV-gp120 in their serum which have an idiotype on the antigen combining sites mimicking that of CD4 molecules. The initial anti-HIV response is accompanied by an anti-idiotypic response producing antibodies which bind to the idiotype structure and also to CD4 molecules on T cells and other cells with this membrane marker, the HIV viral receptor. HIV is blocked by anti-idiotypic antibodies from attaching to normal CD4 cells, preventing cellular infection. Thus, a kit comprising an anti-HIV gp120 idiotype whether bound on a supporting matrix or in solution, when reacted with serum containing a gp120 anti-idiotype, will detect that antibody using appropriate immunoassay methods which may include enzymatic, radioisotope or fluorescent label, thus offering simple alternative testing methods for detection of early HIV infection. A vaccine comprising a purified anti-HIV gp120 antibody with the specific configuration of having an idiotype which mimics a CD4 molecule is also contemplated.



* See back of page

+ DESIGNATIONS OF "SU"

Any designation of "SU" has effect in the Russian Federation. It is not yet known whether any such designation has effect in other States of the former Soviet Union.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MC	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LJ	Liechtenstein	SU+	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark				

PCT/CA91/00404

HIV MARKER/AIDS VACCINE

Field of Invention

This invention relates to the fields of immunology and virology and pertains to immunochemical identification of HIV-1 infection based upon detection of anti-idiotypic antibodies in the serum of HIV-1 infected individuals, and to vaccines for the treatment of HIV.

Background of Invention

The accepted current methods for HIV antibody testing may well be inadequate to detect all people infected with HIV-1. This has also been suggested recently by other investigators using the sensitive, complex and expensive test - PCR (polymerase chain reaction). A pilot study has now identified a new sensitive marker for infection, one that could be used on both small and massive scales, e.g., to monitor volunteer blood donations by the Red Cross.

This marker is a novel serum autoantibody (serological marker referred to as anti-idiotypic antibody) which has the unique property of specifically reacting to both special determinants (called idiotypes) on the antigen combining sites of anti-HIV gp120 antibody and CD4 molecules on T lymphocytes. It is proposed that these antibodies may have a protective role against HIV infectivity and spread during the asymptomatic period of HIV infection. The mechanism by which anti-HIV anti-idiotypic antibodies might provide protection during the early "latency" period and the immunologic mechanisms leading to the loss of protection and progression of disease is currently being investigated.

SUBSTITUTE SHEET

Acquired immune deficiency syndrome (AIDS) is a disorder caused by infection with Human Immunodeficiency Virus (HIV). Infection with HIV in some individuals results in a profound immunological defect resulting in opportunistic infections with devastating results and eventual death of the patient. In other individuals, HIV infection may produce no pathological complications or may result in mild to moderate abnormalities, collectively termed AIDS Related Complex (ARC). The factors responsible for the progression from ARC to AIDS are not known. Furthermore, it is also not known whether all individuals who are asymptomatic seropositives eventually progress to AIDS and while most do, some do not. The elements that control these dynamics remain to be defined.

The mechanism of this profound immune deficiency is also not completely clear. Although there is considerable evidence to suggest that infection of CD4⁺ (helper/inducer) T lymphocytes by HIV results in the death of these cells, this may or may not be an important cause of immune deficiency. The molecular mechanisms involved in this cell death are also not clear, although direct cytotopathic effect, cell fusion and giant cell formation resulting in cell death and lymphotoxin production have all been postulated. All these mechanisms, however, fall short of explaining a number of observations which are contrary to cell death as the only mechanism of immune deficiency in this disease. For example,

3

it has been observed that in patients who are positive for HIV, only 1:100 to 1:100,000 CD4⁺ T cells are infected with the virus. Moreover, immunoglobulin levels in AIDS patients are often higher than controls. This paradoxical observation has been explained on the basis of a hypothetical polyclonal stimulation of B cells (similar to Pokeweed mitogen) by HIV. However, HIV antigens, on the contrary, have been shown to inhibit mitogen responses of peripheral blood lymphocytes and T cells from AIDS patients respond poorly to mitogens. Recently, it has been shown that the FcRIII receptor on human macrophages and possibly another Fc receptor on human CD4 lymphocytes can mediate antibody-dependent enhancement of HIV infectivity and that this phenomenon proceeds through a mechanism independent of the CD4 receptor.

The antibody response of HIV infected patients to HIV antigens is well known. It appears that early in the infection patients make antibodies to both the core proteins (gag gene to make Pr55 and enzymatic cleavage to p17, p24 and a p15*) and the envelope proteins (env gene to make gp160 and enzymatic cleavage to gp120 and gp41) of the virus. However, with the progression of the disease the antibodies to core proteins are diminished or disappear while the antibodies to envelope proteins remain elevated. It has also been shown that a large percentage of AIDS patients have circulating immune complexes in their sera suggestive of an infectious etiology since isolated immune complex material from such

4

patients has significant quantities of HIV antigen or antibody. Recent reports have indicated the presence of auto-antibodies reactive against cardiolipin and HIV-1 accessory gene products such as viral negative factor (nef), rev, tat, vpu and vpr, lymphocytes, etc. Taken together, all these observations suggest that other mechanisms of immunosuppression may in fact be operative in these patients and may indeed contribute significantly in the induction and maintenance of immunosuppression in AIDS.

The high frequency and high titre of anti-HIV gp120 antibodies in the serum of infected subjects would be expected to provide protection from progression to AIDS. On the contrary, infected individuals can progress to AIDS, even in the presence of antibodies to HIV-gp120. Thus, antibodies as such appear to have little or no correlation with immune protection against the development of AIDS. The significance of these antibodies in HIV infected subjects remains elusive. One such mechanism that has not yet been studied in these patients is the down-regulation of the immune response by auto-anti-idiotypic antibodies, although this has recently been postulated as a mechanism of immunosuppression in AIDS. An AIDS-related cytotoxic auto-antibody that reacts with CD4⁺ T cells has been shown to be present in the serum of patients with AIDS and ARC.

In AIDS, it is clear now that the CD4 molecule is important in HIV attachment, penetration and eventual death

WO 92/08983

PCT/CA91/00404

5

of helper T cells and, in fact, is the viral receptor per se. Moreover, there have been several demonstrations of anti-lymphocyte antibodies in the serum of individuals infected with HIV. In most cases, reactivity did not seem to be directed towards a specific lymphocyte population. However, others have demonstrated that these antibodies did not bind at random but reacted predominately with CD2+/CD4+ cells. Some studies indicate that the CD4 molecule is masked by circulating antibodies in AIDS patients. The genesis of such antibodies and their contribution to the pathogenesis of the immune deficit during HIV infection have not been fully investigated. A statistical link has recently been demonstrated between the presence of anti-lymphocyte antibodies (i.e. anti- CD4+ T cells) and the progression to AIDS. 176/200 (88%) AIDS patients and 4/50 (8%) HIV-seropositive non-AIDS patients had significant levels of anti-CD4+ antibodies. In patients with ARC, 64% were found to be positive for anti- CD4+ antibodies, and in 59% of these, the disease progressed to AIDS within 30 months. Interestingly, the 36% who had no significant levels of antibodies had no progression. Recent studies have indicated that 10% of HIV-1 infected individuals produce antibodies that recognize the extracellular portion of the CD4 molecule, a region that is distinct from the virus-binding domain. These studies fail to demonstrate the origin and characteristics of these anti-lymphocyte (CD4 specific) antibodies. Recent reports have

WO 92/08983

PCT/CA91/00404

6

indicated that serum antilymphocyte antibodies could lead to the development of AIDS in HIV-seropositive men. It is noteworthy that before the onset of clinical AIDS, progressors can be distinguished from nonprogressors by markedly different rates of CD4 cell depletion and virus replication. The factors that control these processes remain to be determined. Autoantibodies have been implicated leading to immune damage in AIDS.

For a number of years, the role of anti-idiotypic antibodies in their capacity to suppress immune responses has been studied. Classically, the individual antigenic specificities of homogeneous antibodies or antigen-specific cell receptors are called idiotypes. Antibodies to such idiotypes are referred to as anti-idiotypes. One of the remarkable properties of anti-idiotypic antibodies is the molecular mimicry of biological receptors. For example, measles virus anti-idiotypic inhibits virus infection of primate cells. In this system, it has been reported that (a) anti-idiotypic against anti-measles virus when pre-incubated with Vero cell monolayers, inhibited infection of these cells by measles virus, and (b) anti-idiotypic induced complement-mediated lysis of Vero cells. Thus, anti-idiotypic in the measles system has the potential for binding to and mediating destruction of host cells bearing the measles virus receptor. In other examples, anti-idiotypic antibodies have been shown to react against virus receptors for retrovirus and hepatitis B on infected cells.

WO 92/08983

PCT/CA91/00404

7

Evidence supporting the pathogenic potential of anti-idiotypic antibodies includes the presence of glomerular immune deposits in rabbits with serum sickness induced by chronic intravenous administration of bovine serum albumin (BSA) containing auto-antibodies. Similarly, in mice, immune deposits induced by injection of bacterial lipopoly-saccharide were found to contain idiotypic as well anti-idiotypic immunoglobulin molecules. In addition, anti-idiotypic antibodies (anti-anti-casein) have been shown to be produced in man following milk ingestion. Others have found anti-idiotypic, insulin-mimicking antibodies in the blood of some people suffering from the autoimmune form of diabetes mellitus.

These observations suggest that anti-idiotypic antibodies play an important role in AIDS. Anti-idiotypic antibodies can react to the antigenic determinant (idiotypic) of the primary anti-HIV gp120 antibody and thus, even in the absence of persistent viral replication, may cross-react with receptor-bearing CD4⁺ T lymphocytes as well as on other cells (eg. monocytes or neuronal cells). This mechanism of binding can be directed either to a non-viral binding region on the CD4 molecule or to an Fc receptor. Interestingly, HIV gp120 glycoprotein has been shown to share a cross-reacting epitope with a surface protein on activated human monocytes and is involved in antigen presentation. This in turn may potentiate the destruction of non-infected CD4⁺ T cells which in

turn may enhance "opportunistic" infections or even neurological diseases. There is growing recognition that AIDS patients can develop neurological diseases, ranging from peripheral neuropathy to fulminant dementia, with or without a clinically evident immunodeficiency. Explanations for neurological disorders in AIDS have been proposed to be a competitive effect of HIV gp120 for neuroleukin receptors on neurons since there is some homology between gp120 and neuroleukin.

If antigenic mimicry exists between anti-HIV gp120 idotype and CD4 molecule, then anti-idiotypic antibodies could conceivably play a protective role in disease progression.

Object of the Invention

Thus, it is one object of the present invention to provide an improved method for the detection of early HIV infection.

Another object of the present invention is to provide a diagnostic kit for the determination of early HIV infection.

Yet another object of the present invention is to provide a vaccine for treatment of HIV infection.

Brief Statement of Invention

Thus by one aspect of this invention there is provided a method for detecting anti-HIV gp120 anti-idiotypes in a biological fluid comprising: a method of detecting HIV infection in a biological fluid, comprising:

WO 92/08983

PCT/CA91/00404

9

- a) contacting an anti HIV gp120 idio-
type with a biological
fluid under conditions which allow formation of complexes
between anti-HIV gp120 idiotypes and HIV gp anti-idiotypes in
said biological fluid; and
- b) detecting the formation of complexes as an indication
of the presence of HIV gp120 anti-idiotypes in said biologi-
cal fluid.

By another aspect of this invention there is provided a
diagnostic kit for the detection of HIV anti-idiotypic anti-
bodies in patient serum, comprising:

- (a) a supporting matrix having immobilized thereon an anti-
HIV gp120 idio-
type; and
- (b) a labelled antibody directed against a second site on
said idio-
type.

By another aspect of this invention there is provided a
vaccine comprising a purified anti-HIV gp120 antibody with a
specific configuration of an idio-
type which mimics a CD4
molecule.

Brief Description of Drawings

Fig. 1 is a sketch illustrating a model for anti-idio-
typic antibodies in AIDS;

Fig. 2 is a graph illustrating anti-idiotypic reactivi-
ty over time;

Fig. 3 is a histogram of OKT4 binding to MOLTL T cells
and inhibition of binding by anti-idiotypic antibodies in
patient serum;

WO 92/08983

PCT/CA91/00404

10

Detailed Description of Preferred Embodiments

In preliminary work, a commercially obtained affinity purified sheep IgG polyclonal antibody (D7324, International Enzymes, CA) specific for the conserved epitope regions of HIV-1 gp120 has been tested using a synthetic analogue of gp120 called peptide T (Bachem, California). Peptide T also binds CD4. This antibody (D7324) will also have a conserved idio-type. Thus, anti-idiotypic antibodies to the conserved idio-type will not be missed in serum due to HIV antigenic variations. It has been found that the sheep anti-gp120 antibody binds to peptide T in an ELISA assay, and it can be inhibited (64%) from binding to peptide T by Mab OKT4 (Ortho). Mab anti-gp120 from Dupont as well as Mab OKT4 do not bind to peptide T. Some of the ARC patients' serum antibodies exhibited binding to peptide T and were inhibited (in the range 21-80%) by Mab OKT4. From this experiment, the data indicate that the polyclonal sheep anti-gp120 antibody as well as some of the patient's antibodies exhibit an idio-type that behaves as an internal image of CD4 (see Figure 1). In this figure, it is proposed that anti-idiotypic antibody not only binds to the idio-type of anti-HIV gp120, but also to CD4, and thus, may block HIV infectivity.

Furthermore, after biotinylation of the sheep IgG anti-gp120, the antibody was used as a probe to detect anti-idio-type antibodies in HIV-infected patient's serum after isoelectric focusing across a broad pH gradient on agarose

11

gels and capillary blotted onto nitrocellulose paper. After extensive washing and blocking with Tween-20, alkaline phosphatase conjugated streptavidin was added and the reaction developed for color using BCIP (5-bromo-4-chloro-3-indolyl phosphate-p-toluidine) and NBT (nitroblue tetrazolium) (Bio-Rad).

Adsorption of the serum on a protein A column removed the activity. Table 1 summarizes the results.

Table 1.

Frequency of patients positive for anti-idiotypic in serum

Patient Status	Number of patients (+)		Chi-sq	p values
Normal subjects	0/12			
Autoimmune uveitis	0/1	0%		
Asymptomatics	6/9	66%	11.200	8.18×10^{-4}
ARC	15/18	83%	20.000	7.74×10^{-6}
AIDS	2/8	25%	3.333	n.s.
AIDS + PCP	2/8	25%	3.333	n.s.
AIDS + Kaposi's	3/3	100%	15.000	1.08×10^{-4}
AIDS + Wasting	2/2	100%	14.000	1.83×10^{-4}
SERONEGATIVE COHORT	13/13	100%	25.000	5.73×10^{-7}

It is critical to note that there are a large number of patients with ARC, seropositive asymptomatics, and particularly high risk seronegative gay cohort males with detectable anti-idiotypic antibodies in their serum. In addition, patients with Kaposi's and wasting syndrome had detectable

WO 92/08983

PCT/CA91/00404

12

anti-idiotypic antibodies. In contrast, only a few patients with AIDS and PCP had detectable anti-idiotypic antibody. Our control subjects, including normal, healthy individuals (0/12), a patient with autoimmune uveitis (0/1), normal subjects (data not in figure) immunized with influenza vaccine (0/4), individuals infected with measles (1/3), CMV (0/2), mumps (0/2) or VZ (0/3), have very little or no detectable amounts of serum anti-HIV anti-idiotypic antibodies.

Seronegative gay males were chosen for their known history of frequent sexual contacts with persons diagnosed as ARC or AIDS. Although the presence of strong anti-idiotypic antibody reactions suggests that they are infected with HIV, all 13 persons remain well to date after up to 5 years of follow-up. In an early study, 20/21 seronegative gay males seroconverted with a positive PCR for HIV, and the one who remained seronegative had a positive PCR test for HIV. In a three month follow-up study, 3 of 3 patients showed marked increases in their anti-idiotypic reactivity (Figure 2). In a recent report, others have shown that a select seronegative cohort group at high risk for HIV infection had circulating B cells that, upon in vitro polyclonal activation with pokeweed mitogen, produced anti-HIV antibodies which correlated well with PCR analysis of DNA of their cells for HIV-specific sequences.

Furthermore, adsorption of the serum on a protein A column which has an affinity for IgG antibodies, essentially removes the activity, suggesting that the anti-idiotypic

WO 92/08983

PCT/CA91/00404

13

antibodies are of the IgG isotype. In another study, patient's serum previously determined to have strong anti-idiotypic antibodies reactivity was selected, and its binding to CD4 molecules on MOLT-4 cell lines determined. In this experiment, a blocking assay was used in which serum antibodies would block FITC conjugated Mab OKT4 from binding to CD4 on MOLT-4 T cells, using flow cytometry. As shown in Figure 3, a typical histogram of OKT4 binding to MOLT-4 cells and inhibition of binding by serum #77 (1/100 dilution) containing anti-HIV anti-idiotypic antibodies. The same serum #77 inhibited Mab OKT4 staining of MOLT-4 cells by 38% at 1/10 dilution, by 27% at 1/1000 dilution.

From the above, it is clear that a diagnostic method and apparatus for the detection of HIV infection can be developed.

The method and test kit is a qualitative as well as a quantitative, non-instrumental, test strip enzyme immunoassay for anti-HIV gp120 idiotype antibody in patient serum, which is based on the activity of a tracer. The total HIV anti-idiotypic antibody enzyme immuno-assay kit is a two sites method using two antibodies, monoclonal or polyclonal, directed against two different parts of the protein in question. The first antibody, or idio type thereof, may be fixed on a supporting matrix, such as a nitrocellulose or nylon disk, preferably mounted for ease of handling at one end of a plastic strip, the second antibody is labelled with an enzyme, such as an alkaline phosphatase.

14

There are three essential components for the enzymiomatic assay: (a) a supporting matrix, such as a dry nitrocellulose or nylon disk, preferably, but not essentially, attached to a plastic strip for ease of handling, to which has been immobilized a specific monoclonal or polyclonal antibody, or idiotype thereof against the antibody of interest, namely an HIV gp120 idiotypic antibody such as a sheep IgG polyclonal antibody (D7324, International Enzymes, CA) specific for the conserved epitope regions of HIV-1 gp120; (b) an enzyme reagent containing an alkaline phosphatase conjugate of a second monoclonal or polyclonal antibody directed against a different site on the protein of interest, such as alkaline phosphatase conjugated goat anti-IgG and (c) a colour developer solution containing substrate for the enzyme, such as BCIP (5-bromo-4-chloro-3-indolyl phosphate-p-toluidine) and NBT (nitroblue tetrazolium) (supplied by Bio-Rad, CA).

It will be appreciated, however, that other forms of immuno-assay kits are also contemplated by this invention. For example, the labelled antibody may equally well be labelled with a radioisotope or a fluorescent material.

Example

Patient serum samples were transferred to a container, and an antibody test strip comprising D7324 (sheep IgG polyclonal antibody) on a dry nitrocellulose disk was inserted into the samples and incubated at ambient temperature for 30

15

minutes with agitation. The strip was then removed and washed extensively in a buffer solution. The strip was then immersed in a tracer solution containing Tween-20^R, and an alkaline phosphatase conjugated goat anti-IgG and incubated for 1 hour with agitation (overnight without agitation). The strip was then washed in buffer solution and dipped into a colour developer solution containing 5-bromo-4-chloro-3-indolyl phosphate-p-toluidine and nitroblue tetrazolium. The disk showed an insoluble blue product resulting from coupled enzyme reactions involving the enzyme, alkaline phosphatase and its substrate. The colour intensity was related quantitatively to the amount of the anti-HIV gp120 antibody in the patient serum and it was possible to construct a result table of known amounts of protein as well as negative controls.

As previously noted, mimicry between anti-HIV gp120 idiotype and the CD4 molecule provides a means of protection against HIV progression. Thus a vaccine comprising a purified anti-HIV gp120 antibody with a specific configuration which mimics the CD4 molecule should have therapeutic value in inhibiting progression of the HIV positive patient to full blown AIDS.

We Claim:

1. A method of detecting HIV infection in a biological fluid, comprising:
 - a) contacting an anti-HIV gp120 idio type with a biological fluid under conditions which allow formation of complexes between anti-HIV gp120 idiotypes and HIV gp anti-idiotypes in said biological fluid; and
 - b) detecting the formation of complexes as an indication of the presence of HIV gp120 anti-idiotypes in said biological fluid.
2. A method as claimed in claim 1 characterized by providing a supporting matrix on which is immobilized anti-HIV gp120 idio type; incubating said supporting matrix with a sample of said biological fluid; separating said supporting matrix from the sample and determining the antibody bound to the supporting matrix as an indication of the presence of HIV gp120 anti-idio type in the biological fluid.
3. A method as claimed in claim 2 characterized in that the step of determining the antibody bound to the supporting matrix comprises: incubating the supporting matrix with a labelled antibody which is directed against a second site on the HIV gp120 anti-idio type; separating the supporting matrix from the labelled antibody; and detecting the label associated with the supporting matrix as an indication of HIV gp120 anti-idio type in the biological fluid.

WO 92/08983

PCT/CA91/00404

17

4. A method as claimed in claim 3 characterized in that said label is selected from the group consisting of an enzyme, a radioisotope and a fluorescent material.

5. A method as claimed in claim 4 characterized in that said label is an enzyme reagent conjugated to said antibody directed against a second site on said idio type, and further characterized by immersing said enzyme treated matrix in a colour developer solution containing a substrate for said enzyme to thereby produce an insoluble colour deposit on said matrix indicative of the presence of HIV gp120 idio types in said biological fluid.

6. A method as claimed in any of claims 1-5 characterized in that biological fluid is selected from human serum and human plasma.

7. A method as claimed in any of claims 1-6 characterized in that said anti-HIV gp120 idio type is directed against a conserved epitope of gp120.

8. A method as claimed in any of claims 1-7 characterized in that said labelled antibody is labelled anti-human IgG antibody.

9. A method as claimed in claim 5 characterized in that said anti-HIV gp120 idio type is a sheep IgG polyclonal antibody specific for a conserved epitope region of HIV-1 gp120.

18

10. A method as claimed in claim 9 characterized in that said solution containing an enzyme reagent comprises alkaline phosphatase conjugated goat anti-IgG.
11. A method as claimed in claim 9 characterized in that said enzyme reagent comprises alkaline phosphatase conjugated streptavidin.
12. A method as claimed in claim 10 characterized in that said colour developer solution comprises 5-bromo-4-chloro-3-indolyl phosphate-p-toluidine and nitroblue tetrazolium.
13. A kit for detecting HIV gp120 anti-idiotypic in a biological fluid, comprising, in separate containers, the components:
 - (a) a supporting matrix on which is immobilized anti-HIV gp120 idiotypic; and
 - (b) a labelled antibody directed against a second site on the anti-idiotypic.
14. A kit as claimed in claim 13 characterized in that said labelled antibody is selected from the group consisting of an enzyme conjugated antibody, a radioisotope labelled antibody and a fluorescent labelled antibody.
15. A kit as claimed in claim 14 wherein said labelled antibody is an enzyme conjugated antibody, and further characterized in that said kit includes a colour developer solution containing substrate for said enzyme.

WO 92/08983

PCT/CA91/00404

19

16. A kit as claimed in claim 14 or 15 characterized in that said immobilized anti-HIV gp120 idiotype is a sheep IgG polyclonal antibody specific for conserved epitope regions of HIV-1 gp120.

17. A composition for treatment of HIV infection comprising HIV gp120 anti-idiotype, in an amount effective to block HIV infection of CD4 receptor-bearing cells, in a physiologically acceptable carrier.

18. A vaccine comprising a purified anti-HIV gp120 antibody with a specific configuration of having an idiotype which mimics a CD4 molecule.

19. A vaccine as claimed in claim 18 characterized in that said antibody is an affinity purified antibody.

20. A vaccine as claimed in claim 18 characterized in that said antibody is a monoclonal antibody.

21. A method of treating HIV infection comprising administering the vaccine of claims 18, 19 or 20 to an HIV infected subject.

WO 92/08983

PCT/CA91/00404

1/3





FIGURE 1

SUBSTITUTE SHEET

WO 92/08983

PCT/CA91/00404


2/3

**SERONEGATIVES: FREQUENT SEXUAL
CONTACTS WITH HIV INFECTED PATNERS****FIGURE 2****SUBSTITUTE SHEET**

WO 92/08983

PCT/CA91/00404

3/3

**FIGURE 3****SUBSTITUTE SHEET**

INTERNATIONAL SEARCH REPORT

PCT/CA 91/00404

International Application No

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all)⁵

According to International Patent Classification (IPC) or to both National Classification and IPC

Int.Cl. 5 G01N33/569; G01N33/68; C07K15/00; C12P21/00
A61K39/395

II. FIELDS SEARCHED

Minimum Documentation Searched⁷

Classification System

Classification Symbols

Int.Cl. 5 G01N ; C07K ; A61K ; C12P

Documentation Searched other than Minimum Documentation
to the extent that such Documents are included in the Fields Searched⁸

III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹

Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
Y	THE JOURNAL OF IMMUNOLOGY vol. 145, no. 7, 1 October 1990, BALTIMORE MD USA pages 2199 - 2206; M.S.C. FUNG ET AL: 'MONOCLONAL ANTI-IDIOTYPIC ANTIBODY MIMICKING THE PRINCIPAL NEUTRALISATION SITE IN HIV - 1 GP 120 INDUCES HIV - 1 NEUTRALIZING ANTIBODIES IN RABBITS.' See whole article.	1-16
Y	R.A. MORISSET. 'V International conference on aids: the scientific and social challenge.' 1989, INTERNATIONAL DEVELOPMENT RESEARCH CENTRE , OTTAWA ONTARIO CANADA See page 650 abstract nr. c.553 : J.J. Drabick et al : "Naturally occurring auto-antibodies to CD4 and the MHC class II molecule in HIV - infected patients".	1-16

¹⁰ Special categories of cited documents :^A document defining the general state of the art which is not considered to be of particular relevance^E earlier document but published on or after the international filing date^L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)^O document referring to an oral disclosure, use, exhibition or other means^P document published prior to the international filing date but later than the priority date claimed^T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention^X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step^Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.^Z document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search

Date of Mailing of this International Search Report

17 FEBRUARY 1992

02 MAR 1992

International Searching Authority

Signature of Authorized Officer

EUR PEAN PATENT OFFICE

VAN BOHEMEN C.G.

International Application No

PCT/CA 91/00404

III. DOCUMENTS CONSIDERED TO BE RELEVANT

(CONTINUED FROM THE SECOND SHEET)

Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
X	WO, A, 8 809 181 (TANOX BIOSYSTEMS) 1 December 1988 see page 16, line 6 - line 10 see page 95, line 6 - line 23	18-21
A	S.D. PUTNEY AND D.P. BOLOGNESI 'Aids vaccine research and clinical trials.' June 1990, MARCEL DEKKER INC, NEW YORK NY USA See chapter 11 on page 241: R.C. Kennedy et al. ; "CD4-gp120 interaction. Idiotypic mimicry as putative vaccines and therapeutics against hiv infection".	1-21

Form PCT/ISA/210 (extra sheet) (January 1985)

